Immunological Mechanisms Underneath the Efficacy of Cancer Therapy

The hallmarks of cancer

Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219 · see citing works

Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · see citing works

The future of immune checkpoint therapy

Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · see citing works

Neoantigens in cancer immunotherapy

Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783 · see citing works

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · see citing works

Immunogenic cell death and DAMPs in cancer therapy

Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223 · see citing works

Calreticulin exposure dictates the immunogenicity of cancer cell death

Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216 · see citing works

Immunogenic cell death in cancer and infectious disease

Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119 · see citing works

Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 2× · see citing works

IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896 · see citing works

T cell exclusion, immune privilege, and the tumor microenvironment

Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,494 · see citing works

Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy

Kärre, K., Ljunggren, H., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,333 · see citing works

Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment

Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251 · see citing works

HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C

Braud, V. M., Allan, D., O'Callaghan, C. A., Söderström, K., D’Andrea, A., Ogg, G. S., Lazetic, S., Young, N. T., Bell, J. I., Phillips, J. H., et al. (1998) · Nature · doi:10.1038/35869 · Cited by 2,226 · see citing works

Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis

Chang, C.-H., Curtis, J. D., Maggi, L. B., Faubert, B., Villarino, A. V., O’Sullivan, D., Huang, S. C.-C., van der Windt, G. J. W., Blagih, J., Qiu, J., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.016 · Cited by 2,204 · see citing works

The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide

Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050 · see citing works

Towards a systems understanding of MHC class I and MHC class II antigen presentation

Neefjes, J., Jongsma, M. L. M., Paul, P., & Bakke, O. (2011) · Nature Reviews Immunology · doi:10.1038/nri3084 · Cited by 2,044 · see citing works

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022 · see citing works

A History of Cancer Chemotherapy

DeVita, V. T., & Chu, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6611 · Cited by 1,973 · see citing works

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898 · see citing works

Immunological effects of conventional chemotherapy and targeted anticancer agents

Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530 · see citing works

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512 · see citing works

Adaptive immunity maintains occult cancer in an equilibrium state

Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,438 · see citing works

Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice

Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377 · see citing works

5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity

Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245 · see citing works

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, É., Cesne, A. L., Zitvogel, L., & Chauffert, B. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,241 · see citing works

Autophagy in malignant transformation and cancer progression

Galluzzi, L., Pietrocola, F., Bravo‐San Pedro, J. M., Amaravadi, R. K., Baehrecke, E. H., Cecconi, F., Codogno, P., Debnath, J., Gewirtz, D. A., Karantza, V., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490784 · Cited by 1,182 · see citing works

Immunogenic death of colon cancer cells treated with oxaliplatin

Tesnière, A., Schlemmer, F., Boige, V., Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apétoh, L., Barault, L., et al. (2009) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,177 · see citing works

History of myeloid-derived suppressor cells

Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148 · see citing works

Cellular Oncogenes and Multistep Carcinogenesis

Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Science · doi:10.1126/science.6356358 · Cited by 1,107 · see citing works

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

Huang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099 · see citing works

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054 · see citing works

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042 · see citing works

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability

Mlecnik, B., Bindea, G., Angell, H. K., Maby, P., Angelova, M., Tougeron, D., Church, S. E., Lafontaine, L., Fischer, M., Fredriksen, T., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.025 · Cited by 1,034 · see citing works

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

Denkert, C., von Minckwitz, G., Brase, J. C., Sinn, B. V., Gade, S., Kronenwett, R., Pfitzner, B. M., Salat, C., Loi, S., Schmitt, W., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1967 · Cited by 1,026 · see citing works

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

Pfirschke, C., Engblom, C., Rickelt, S., Cortez‐Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 944 · see citing works

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

Ghiringhelli, F., Larmonier, N., Schmitt, E., Parcellier, A., Cathelin, D., Garrido, C., Chauffert, B., Solary, É., Bonnotte, B., & Martin, F. (2004) · European Journal of Immunology · doi:10.1002/eji.200324181 · Cited by 878 · see citing works

Regulation of Ligands for the NKG2D Activating Receptor

Raulet, D. H., Gasser, S., Gowen, B. G., Deng, W., & Jung, H. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095951 · Cited by 850 · see citing works

Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death

Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A., Chapman, D. C., Durchschlag, M., Joza, N., Pierron, G., van Endert, P., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.1 · Cited by 848 · see citing works

Metabolic targets for cancer therapy

Galluzzi, L., Kepp, O., Heiden, M. G. V., & Kroemer, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4145 · Cited by 705 · see citing works

VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer

Terme, M., Pernot, S., Marcheteau, E., Sandoval, F., Benhamouda, N., Colussi, O., Dubreuil, O., Carpentier, A. F., Tartour, E., & Taieb, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2325 · Cited by 684 · see citing works

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676 · see citing works

Dendritic Cells in Tumor-Associated Tertiary Lymphoid Structures Signal a Th1 Cytotoxic Immune Contexture and License the Positive Prognostic Value of Infiltrating CD8+ T Cells

Goc, J., Germain, C., Vo-Bourgais, T. K. D., Mansuet‐Lupo, A., Klein, C., Knockaert, S., de Chaisemartin, L., Ouakrim, H., Becht, É., Alifano, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1342 · Cited by 675 · see citing works

Metronomic chemotherapy: new rationale for new directions

Pasquier, E., Kavallaris, M., & André, N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.82 · Cited by 655 · see citing works

Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death

Golden, E. B., Frances, D., Pellicciotta, I., Demaria, S., Barcellos‐Hoff, M. H., & Formenti, S. C. (2014) · OncoImmunology · doi:10.4161/onci.28518 · Cited by 628 · see citing works

Conditioning regimens for hematopoietic cell transplantation: one size does not fit all

Gyurkocza, B., & Sandmaier, B. M. (2014) · Blood · doi:10.1182/blood-2014-02-514778 · Cited by 616 · see citing works

Natural killer cell memory in infection, inflammation and cancer

Cerwenka, A., & Lanier, L. L. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2015.9 · Cited by 578 · see citing works

From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer

Angell, H., & Galon, J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.03.004 · Cited by 574 · see citing works

Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4

Probst, H. C., McCoy, K. D., Okazaki, T., Honjo, T., & van den Broek, M. F. (2005) · Nature Immunology · doi:10.1038/ni1165 · Cited by 554 · see citing works

Radiation-Induced IFN-γ Production within the Tumor Microenvironment Influences Antitumor Immunity

Lugade, A. A., Sorensen, E. W., Gerber, S. A., Moran, J. P., Frelinger, J. G., & Lord, E. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.3132 · Cited by 485 · see citing works

Reversing T-cell Dysfunction and Exhaustion in Cancer

Zarour, H. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1849 · Cited by 462 · see citing works

Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1

Vacchelli, E., Ma, Y., Baracco, E. E., Sistigu, A., Enot, D. P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., et al. (2015) · Science · doi:10.1126/science.aad0779 · Cited by 452 · see citing works

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

Liu, L., Mayes, P. A., Eastman, S., Shi, H., Yadavilli, S., Zhang, T., Yang, J., Seestaller-Wehr, L., Zhang, S.-Y., Hopson, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2339 · Cited by 446 · see citing works

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers

Li, H., Chiappinelli, K. B., Guzzetta, A. A., Easwaran, H., Yen, R.-W. C., Vatapalli, R. J., Topper, M. J., Luo, J., Connolly, R. M., Azad, N. S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1782 · Cited by 428 · see citing works

Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?

Löb, S., Königsrainer, A., Rammensee, H., Opelz, G., & Terness, P. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2639 · Cited by 421 · see citing works

Combinatorial Strategies for the Induction of Immunogenic Cell Death

Bezu, L., Gomes-da-Silva, L. C., Dewitte, H., Breckpot, K., Fucikova, J. P., Špíšek, R., Galluzzi, L., Kepp, O., & Kroemer, G. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00187 · Cited by 389 · see citing works

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses

Liu, W. M., Fowler, D. W., Smith, P., & Dalgleish, A. G. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605465 · Cited by 356 · see citing works

Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer

Brambilla, E. M., Teuff, G. L., Marguet, S., Lantuéjoul, S., Dunant, A., Graziano, S. L., Pirker, R., Douillard, J.-Y., Chevalier, T. L., Filipits, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0970 · Cited by 351 · see citing works

Radiation as an immunological adjuvant: current evidence on dose and fractionation

Demaria, S., & Formenti, S. C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00153 · Cited by 333 · see citing works

Natural and therapy-induced immunosurveillance in breast cancer

Kroemer, G., Senovilla, L., Galluzzi, L., André, F., & Zitvogel, L. (2015) · Nature Medicine · doi:10.1038/nm.3944 · Cited by 308 · see citing works

Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors

Rusakiewicz, S., Semeraro, M., Sarabi, M., Desbois, M., Locher, C., Mendez, R., Vimond, N., Concha, Á., Garrido, F., Isambert, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0371 · Cited by 304 · see citing works

Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.

Demaria, S., Volm, M., Shapiro, R. L., Yee, H. T., Oratz, R., Formenti, S. C., Muggia, F. M., & Symmans, W. F. (2001) · PubMed · Cited by 303 · see citing works

Chemotherapeutics and Radiation Stimulate MHC Class I Expression through Elevated Interferon-beta Signaling in Breast Cancer Cells

Wan, S., Pestka, S., Jubin, R. G., Lyu, Y. L., Tsai, Y.-C., & Liu, L. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032542 · Cited by 295 · see citing works

The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death

Pozzi, C., Cuomo, A., Spadoni, I., Magni, E., Silvola, A., Conte, A., Sigismund, S., Ravenda, P. S., Bonaldi, T., Zampino, M. G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4078 · Cited by 292 · see citing works

Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model

Sevko, A., Michels, T., Vrohlings, M., Umansky, L., Beckhove, P., Kato, M., Shurin, G. V., Shurin, M. R., & Umansky, V. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202781 · Cited by 247 · see citing works

Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors

Epling‐Burnette, P. K., Bai, F., Painter, J. S., Rollison, D. E. M., Salih, H. R., Krusch, M., Zou, J., Ku, E., Zhong, B., Boulware, D. C., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035519 · Cited by 232 · see citing works

Mutational Landscape and Sensitivity to Immune Checkpoint Blockers

Chabanon, R. M., Pedrero, M., Lefèbvre, C., Marabelle, A., Soria, J., & Postel-Vinay, S. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0903 · Cited by 232 · see citing works

Metabolic crosstalk between host and pathogen: sensing, adapting and competing

Olive, A. J., & Sassetti, C. M. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.12 · Cited by 228 · see citing works

The biology and management of systemic anaplastic large cell lymphoma

Hapgood, G., & Savage, K. J. J. (2015) · Blood · doi:10.1182/blood-2014-10-567461 · Cited by 207 · see citing works

Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor–Bearing Patients

Ménard, C., Blay, J.-Y., Borg, C., Michiels, S., Ghiringhelli, F., Robert, C., Nonn, C., Chaput, N., Taïeb, J., Delahaye, N. F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3807 · Cited by 202 · see citing works

Ligands for natural killer cell–activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias

Nowbakht, P., Ionescu, M.-C. S., Rohner, A., Kalberer, C. P., Rossy, E., Mori, L., Cosman, D. J., Libero, G. D., & Wodnar‐Filipowicz, A. (2005) · Blood · doi:10.1182/blood-2004-07-2585 · Cited by 194 · see citing works

Myeloid-Derived Suppressor Cell Inhibition of the IFN Response in Tumor-Bearing Mice

Mundy-Bosse, B. L., Lesinski, G. B., Jaime‐Ramirez, A. C., Benninger, K. L., Khan, M., Kuppusamy, P., Guenterberg, K. D., Kondadasula, S. V., Chaudhury, A. R., Perle, K. M. D. L., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2670 · Cited by 189 · see citing works

RAE1 Ligands for the NKG2D Receptor Are Regulated by STING-Dependent DNA Sensor Pathways in Lymphoma

Lam, A. R., Bert, N. L., Ho, S. S. W., Shen, Y. J., Tang, M. L. F., Xiong, G. M., Croxford, J. L., Koo, C. X., Ishii, K. J., Akira, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1703 · Cited by 179 · see citing works

Cisplatin Resistance Associated with PARP Hyperactivation

Michels, J., Vitale, I., Galluzzi, L., Adam, J., Olaussen, K. A., Kepp, O., Senovilla, L., Talhaoui, I., Guegan, J., Enot, D. P., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3000 · Cited by 176 · see citing works

Adverse Immunoregulatory Effects of 5FU and CPT11 Chemotherapy on Myeloid-Derived Suppressor Cells and Colorectal Cancer Outcomes

Kanterman, J., Sade-Feldman, M., Biton, M., Ish‐Shalom, E., Lasry, A., Goldshtein, A., Hubert, A., & Baniyash, M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0657 · Cited by 166 · see citing works

Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice

Pfannenstiel, L. W., Lam, S. S. K., Emens, L. A., Jaffee, E. M., & Armstrong, T. D. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.03.001 · Cited by 160 · see citing works

Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer

Fucikova, J., Moserova, I., Urbanova, L., Bezu, L., Kepp, O., Cremer, I., Salek, C., Strnad, P., Kroemer, G., Galluzzi, L., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00402 · Cited by 159 · see citing works

Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer

Li, J.-Y., Duan, X.-F., Wang, L.-P., Xu, Y.-J., Huang, L., Zhang, T.-F., Liu, J.-Y., Li, F., Zhang, Z., Yue, D.-L., et al. (2014) · Journal of Immunology Research · doi:10.1155/2014/286170 · Cited by 157 · see citing works

MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro

Angell, T. E., Lechner, M. G., Jang, J. K., LoPresti, J. S., & Epstein, A. L. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0879 · Cited by 153 · see citing works

Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients

Desar, I. M. E., Jacobs, J. F. M., Hulsbergen‐vandeKaa, C. A., Oyen, W. J. G., Mulders, P., van der Graaf, W. T. A., Adema, G. J., van Herpen, C. M. L., & de Vries, I. J. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25674 · Cited by 138 · see citing works

Downregulation of MHC-I Expression Is Prevalent but Reversible in Merkel Cell Carcinoma

Paulson, K. G., Tegeder, A. R., Willmes, C., Iyer, J. G., Afanasiev, O. K., Schrama, D., Koba, S., Thibodeau, R. M., Nagase, K., Simonson, W. T., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0005 · Cited by 132 · see citing works

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

Buqué, A., Bloy, N., Aranda, F., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Marabelle, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008814 · Cited by 130 · see citing works

Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-γ by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells

Hodge, G. L., Barnawi, J., Jurisevic, C. A., Moffat, D., Holmes, M., Reynolds, P. N., Jersmann, H. P. A., & Hodge, S. J. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12392 · Cited by 127 · see citing works

Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ

Ho, P.-C., Meeth, K. M., Tsui, Y.-C., Srivastava, B., Bosenberg, M. W., & Kaech, S. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3461 · Cited by 126 · see citing works

The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer

Ladoire, S., Enot, D., Senovilla, L., Ghiringhelli, F., Poirier-Colame, V., Chaba, K., Semeraro, M., Chaix, M., Penault-Llorca, F., Arnould, L., et al. (2016) · Autophagy · doi:10.1080/15548627.2016.1154244 · Cited by 117 · see citing works

Lapatinib and doxorubicin enhance the S tat1‐dependent antitumor immune response

Hannesdóttir, L., Tymoszuk, P., Parajuli, N., Wasmer, M.-H., Philipp, S., Daschil, N., Datta, S., Koller, J., Tripp, C. H., Stoitzner, P., et al. (2013) · European Journal of Immunology · doi:10.1002/eji.201242505 · Cited by 113 · see citing works

Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice

González-Aparicio, M., Alzuguren, P., Mauleón, I., Medina‐Echeverz, J., Hervás‐Stubbs, S., Mancheño, U., Berraondo, P., Crettaz, J. S., González‐Aseguinolaza, G., Prìeto, J., et al. (2010) · Gut · doi:10.1136/gut.2010.211722 · Cited by 112 · see citing works

The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible “hard” lesions

Garrido, F., Algarra, I., & Garcia-Lora, A. M. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0893-2 · Cited by 98 · see citing works

Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8 + T-cell responses and immune memory

Wu, J., & Waxman, D. J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1005521 · Cited by 97 · see citing works

Development of Minimal Residual Disease–Directed Therapy in Acute Myeloid Leukemia

Freeman, S. D., Jovanovic, J. V., & Grimwade, D. J. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.009 · Cited by 90 · see citing works

Tumor‐infiltrating dendritic cells exhibit defective cross‐presentation of tumor antigens, but is reversed by chemotherapy

McDonnell, A. M., Lesterhuis, W. J., Khong, A., Nowak, A. K., Lake, R., Currie, A. J., & Robinson, B. W. S. (2014) · European Journal of Immunology · doi:10.1002/eji.201444722 · Cited by 87 · see citing works

Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways

Sawant, A., Schafer, C. C., Jin, T. H., Zmijewski, J. W., Tse, H. M., Roth, J. C., Sun, Z., Siegal, G. P., Thannickal, V. J., Grant, S. C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0987 · Cited by 87 · see citing works

Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer

Colangelo, T., Polcaro, G., Ziccardi, P., Pucci, B., Muccillo, L., Galgani, M., Fucci, A., Milone, M. R., Budillon, A., Santopaolo, M., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.28 · Cited by 87 · see citing works

Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer

Homma, Y., Taniguchi, K., Nakazawa, M., Matsuyama, R., Mori, R., TAKEDA, K., Ichikawa, Y., Tanaka, K., & Endo, I. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-013-1079-0 · Cited by 83 · see citing works

Considerations for the successful co-development of targeted cancer therapies and companion diagnostics

Fridlyand, J., Simon, R. M., Walrath, J. C., Roach, N., Buller, R. E., Schenkein, D. P., Flaherty, K. T., Allen, J. D., Sigal, E. V., & Scher, H. I. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4101 · Cited by 81 · see citing works

Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation

He, S., Yin, T., Li, D., Gao, X., Wan, Y., Ma, X., Ye, T., Guo, F., Sun, J., Lin, Z., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-186 · Cited by 75 · see citing works

Effect of Pemetrexed on Innate Immune Killer Cells and Adaptive Immune T Cells in Subjects With Adenocarcinoma of the Pancreas

Davis, M., Conlon, K. C., Bohac, G. C., Barcenas, J., Leslie, W., Watkins, L., Lamzabi, I., Deng, Y., Li, Y., & PLATE, J. M. D. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31826c8a4f · Cited by 75 · see citing works

Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: Role of uric acid accumulation in gemcitabine-induced MICA/B expression

Xu, X., Rao, G., Groh, V., Spies, T. A., Gattuso, P., Kaufman, H. L., PLATE, J. M. D., & Prinz, R. A. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-194 · Cited by 71 · see citing works

EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells

Kim, H., Kim, S.-H., Kim, M.-J., Kim, S.-J., Park, S.-J., Chung, J.-S., Bae, J.-H., & Kang, C.-D. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31821b724a · Cited by 63 · see citing works

Decreased NKG2D expression on NK cells correlates with impaired NK cell function in patients with gastric cancer

Saito, H., Osaki, T., & Ikeguchi, M. (2011) · Gastric Cancer · doi:10.1007/s10120-011-0059-8 · Cited by 62 · see citing works

Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy

Vacchelli, E., Enot, D. P., Pietrocola, F., Zitvogel, L., & Kroemer, G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0294 · Cited by 59 · see citing works

5-Fluorouracil and Interferon-α Immunochemotherapy Enhances Immunogenicity of Murine Pancreatic Cancer Through Upregulation of NKG2D Ligands and MHC Class I

Khallouf, H., Märten, A., Serba, S., Teichgräber, V., Büchler, M. W., Jäger, D., & Schmidt, J. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31824b3a76 · Cited by 58 · see citing works

Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma

Lowe, D. B., Bose, A., Taylor, J. L., Tawbi, H. A.-H., Lin, Y., Kirkwood, J. M., & Storkus, W. J. (2014) · OncoImmunology · doi:10.4161/onci.27589 · Cited by 47 · see citing works

Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15Rα and NKG2D Triggering

Romero, A. I., Chaput, N., Poirier-Colame, V., Rusakiewicz, S., Jacquelot, N., Chaba, K., Mortier, E., Jacques, Y., Caillat‐Zucman, S., Flament, C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1186 · Cited by 42 · see citing works

Serial Low Doses of Sorafenib Enhance Therapeutic Efficacy of Adoptive T Cell Therapy in a Murine Model by Improving Tumor Microenvironment

Chuang, H., Chang, Y.-F., Liu, R.-S., & Hwang, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109992 · Cited by 38 · see citing works

Immunology of a Transmissible Cancer Spreading among Tasmanian Devils

Woods, G. M., Howson, L. J., Brown, G. K., Tovar, C., Kreiss, A., Corcoran, L. M., & Lyons, A. B. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500131 · Cited by 29 · see citing works

Abstract 5101: Biomarker identification in non-small cell lung cancer (NSCLC) with activity-based proteomics

Wiedl, T., Arni, S., Roschitzki, B., Grossmann, J., Soltermann, A., Hillinger, S., Aebersold, R. H., & Weder, W. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-5101 · Cited by 19 · see citing works

Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor

Kivlin, C. M., Watson, K. L., Sannaa, G. A. A., Belousov, R., Ingram, D. R., Huang, K.-L., May, C. D., Bolshakov, S. V., Landers, S. M., Kalam, A. A., et al. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1108486 · Cited by 16 · see citing works

Long‐term molecular remission with persistence of BCR ‐ ABL 1‐specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia‐positive ALL

Riva, G., Luppi, M., Lagreca, I., Barozzi, P., Quadrelli, C., Vallerini, D., Zanetti, E., Basso, S., Forghieri, F., Morselli, M., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12612 · Cited by 8 · see citing works

Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.

Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680 · see citing works

Mitochondrial control of inflammation

Marchi, S., Guilbaud, E., Tait, S. W. G., Yamazaki, T., & Galluzzi, L. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00760-x · Cited by 1,027 · see citing works

Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics

Garg, A. D., More, S., Rufo, N., Meçe, O., Sassano, M. L., Agostinis, P., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1386829 · Cited by 277 · see citing works

Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology

Vanmeerbeek, I., Sprooten, J., Ruysscher, D. D., Tejpar, S., Vandenberghe, P., Fucikova, J. P., Špíšek, R., Zitvogel, L., Kroemer, G., Galluzzi, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1703449 · Cited by 226 · see citing works

Radiation-induced Cell Death and Its Mechanisms

Jiao, Y., Cao, F., & Liu, H. (2022) · Health Physics · doi:10.1097/hp.0000000000001601 · Cited by 220 · see citing works

Killers 2.0: NK cell therapies at the forefront of cancer control

Hodgins, J. J., Khan, S., Park, M. M., Auer, R. C., & Ardolino, M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129338 · Cited by 213 · see citing works

Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma

Bröckelmann, P. J., Goergen, H., Keller, U. B., Meißner, J., Ordemann, R., Halbsguth, T. V., Sasse, S., Sökler, M., Kerkhoff, A., Mathas, S., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0750 · Cited by 175 · see citing works

White paper on plasma for medicine and hygiene: Future in plasma health sciences

Bekeschus, S., Favia, P., Robert, É., & von Woedtke, T. (2018) · Plasma Processes and Polymers · doi:10.1002/ppap.201800033 · Cited by 172 · see citing works

Trial watch: Peptide-based vaccines in anticancer therapy

Bezu, L., Kepp, O., Cerrato, G., Pol, J. G., Fucikova, J. P., Špíšek, R., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1511506 · Cited by 154 · see citing works

Research progress on morphology and mechanism of programmed cell death

Chen, Y., Li, X., Yang, M., & Liu, S. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06712-8 · Cited by 160 · see citing works

Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer

Wang, Y., Wang, Y., Ren, Y., Zhang, Q., Yi, P., & Cheng, C. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.010 · Cited by 146 · see citing works

Senescence and the tumor-immune landscape: Implications for cancer immunotherapy

Chibaya, L., Snyder, J. T., & Ruscetti, M. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.005 · Cited by 138 · see citing works

Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: an update review

Zhai, J., Gu, X., Liu, Y., Hu, Y., Jiang, Y., & Zhang, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1152934 · Cited by 131 · see citing works

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

Buqué, A., Bloy, N., Aranda, F., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Marabelle, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008814 · Cited by 130 · see citing works

Role of immune-checkpoint inhibitors in lung cancer

Jain, P., Jain, C., & Velcheti, V. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465817750075 · Cited by 125 · see citing works

Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers

Rossi, C., Gilhodes, J., Maerevoet, M., Herbaux, C., Morschhauser, F., Brice, P., Garciaz, S., Borel, C., Ysebaert, L., Obéric, L., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25154 · Cited by 119 · see citing works

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

Borghaei, H., Langer, C. J., Paz‐Ares, L., Rodríguez‐Abreu, D., Halmos, B., Garassino, M. C., Houghton, B., Kurata, T., Cheng, Y., Lin, J., et al. (2020) · Cancer · doi:10.1002/cncr.33142 · Cited by 115 · see citing works

Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans

Knapp, D. W., Dhawan, D., Ramos, J. A., Ratliff, T. L., Cresswell, G. M., Utturkar, S. M., Sommer, B. C., Fulkerson, C. M., & Hahn, N. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01493 · Cited by 108 · see citing works

Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer

Kašíková, L., Raková, J., Hensler, M., Láníčková, T., Tománková, J., Pasulka, J., Drozenová, J., Mojžíšová, K., Fialová, A., Vosahlikova, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46873-w · Cited by 106 · see citing works

Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy

de Leve, S., Wirsdörfer, F., & Jendrossek, V. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00698 · Cited by 93 · see citing works

Perturbing mitosis for anti‐cancer therapy: is cell death the only answer?

Haschka, M. D., Karbon, G., Fava, L. L., & Villunger, A. (2018) · EMBO Reports · doi:10.15252/embr.201745440 · Cited by 89 · see citing works

Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: challenges and updates

Shang, S., Liu, J., Verma, V., Wu, M., Welsh, J. W., Yu, J., & Chen, D. (2021) · 癌症：英文版 · doi:10.1002/cac2.12226 · Cited by 89 · see citing works

Immune recognition of irradiated cancer cells

Wennerberg, E., Vanpouille‐Box, C., Bornstein, S., Yamazaki, T., Demaria, S., & Galluzzi, L. (2017) · Immunological Reviews · doi:10.1111/imr.12568 · Cited by 87 · see citing works

Dna Damage Response Alterations in Gastric Cancer: Knocking down a New Wall

Ricci, A. D., Rizzo, A., & Brandi, G. (2021) · Future Oncology · doi:10.2217/fon-2020-0989 · Cited by 82 · see citing works

Present and future of cancer immunotherapy: A tumor microenvironmental perspective (Review)

Yu, Y., & Cui, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.9219 · Cited by 78 · see citing works

Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity

Hao, D., Liu, J., Chen, M., Li, J., Wang, L., Li, X., Zhao, Q., & Di, L. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3862 · Cited by 75 · see citing works

Trial Watch: Adoptively transferred cells for anticancer immunotherapy

Fournier, C., Martin, F., Zitvogel, L., Kroemer, G., Galluzzi, L., & Apétoh, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1363139 · Cited by 76 · see citing works

Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy

Michelakos, T. P., Cai, L., Villani, V., Sabbatino, F., Kontos, F., Castillo, C. F.-D., Yamada, T., Neyaz, A., Taylor, M. S., Deshpande, V., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa073 · Cited by 75 · see citing works

Nidogen-1 is a novel extracellular ligand for the NKp44 activating receptor

Gaggero, S., Bruschi, M., Petretto, A., Parodi, M., Zotto, G. D., Lavarello, C., Prato, C., Santucci, L., Barbuto, A., Bottino, C., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1470730 · Cited by 74 · see citing works

Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer

Dhawan, D., Hahn, N. M., Ramos, J. A., & Knapp, D. W. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007571 · Cited by 73 · see citing works

Cancer Vaccines: Promising Therapeutics or an Unattainable Dream

Donninger, H., Li, C., Eaton, J. W., & Yaddanapudi, K. (2021) · Vaccines · doi:10.3390/vaccines9060668 · Cited by 70 · see citing works

Trial watch: immune checkpoint blockers for cancer therapy

Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373237 · Cited by 73 · see citing works

Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications

Zhao, B., Wu, B. C., Feng, N., Zhang, X., Zhang, X., Wei, Y., & Zhang, W. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01426-4 · Cited by 65 · see citing works

Immuno-oncology-101: overview of major concepts and translational perspectives

Allard, B., Aspeslagh, S., Garaud, S., Dupont, F., Solinas, C., Kok, M., Routy, B., Sotiriou, C. P., Stagg, J., & Buisseret, L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.005 · Cited by 57 · see citing works

Natural Compounds of Marine Origin as Inducers of Immunogenic Cell Death (ICD): Potential Role for Cancer Interception and Therapy

Sansone, C., Bruno, A., Piscitelli, C., Baci, D., Fontana, A., Brunet, C., Noonan, D. M., & Albini, A. (2021) · Cells · doi:10.3390/cells10020231 · Cited by 53 · see citing works

Potentiating anti-tumor immunity with physical plasma

Bekeschus, S., Clemen, R., & Metelmann, H. (2018) · Clinical Plasma Medicine · doi:10.1016/j.cpme.2018.10.001 · Cited by 51 · see citing works

Exploiting NK Cell Surveillance Pathways for Cancer Therapy

Barrow, A. D., & Colonna, M. (2019) · Cancers · doi:10.3390/cancers11010055 · Cited by 49 · see citing works

Radiation-Induced Transformation of Immunoregulatory Networks in the Tumor Stroma

Martínez-Zubiaurre, I., Chalmers, A. J., & Hellevik, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01679 · Cited by 52 · see citing works

Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies

Sommer, B. C., Dhawan, D., Ratliff, T. L., & Knapp, D. W. (2018) · Bladder Cancer · doi:10.3233/blc-170145 · Cited by 48 · see citing works

Synergizing systemic responses by combining immunotherapy with radiotherapy in metastatic non-small cell lung cancer: The potential of the abscopal effect

Theelen, W. S. M. E., de Jong, M. C., & Baas, P. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.02.015 · Cited by 48 · see citing works

Current Landscape of Immunotherapy for the Treatment of Metastatic Non-Small-Cell Lung Cancer

Pabani, A., & Butts, C. A. (2018) · Current Oncology · doi:10.3747/co.25.3750 · Cited by 48 · see citing works

Ionizing Radiation Curtails Immunosuppressive Effects From Cancer-Associated Fibroblasts on Dendritic Cells

Berzaghi, R., Tornaas, S., Lode, K., Hellevik, T., & Martínez-Zubiaurre, I. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.662594 · Cited by 45 · see citing works

Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors

Bronger, H., Magdolen, V., Goettig, P., & Dreyer, T. F. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09807-3 · Cited by 45 · see citing works

The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival

Santegoets, S. J. A. M., de Groot, A. F., Dijkgraaf, E. M., Simões, A. M. C., van der Noord, V. E., van Ham, J. J., Welters, M. J. P., Kroep, J. R., & van der Burg, S. H. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1465166 · Cited by 44 · see citing works

Diagnosis and treatment of epidural metastases.

Grossman, S. A., & Lossignol, D. (1990) · PubMed · Cited by 40 · see citing works

Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy

Sakaguchi, A., Horimoto, Y., Onagi, H., Ikarashi, D., Nakayama, T., Nakatsura, T., Shimizu, H., Kojima, K., Yao, T., Matsumoto, T., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01477-w · Cited by 38 · see citing works

Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer

Jie, C., Li, R., Cheng, Y., Wang, Z., Wu, Q., & Xie, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1122352 · Cited by 37 · see citing works

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications

Cabo, M., Offringa, R., Zitvogel, L., Kroemer, G., Muntasell, A., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1371896 · Cited by 37 · see citing works

Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy

Joseph, E. L. M., Kirilovsky, A., Lecoester, B., Sissy, C. E., Boullerot, L., Rangan, L., Marguier, A., Tochet, F., Dosset, M., Boustani, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002256 · Cited by 36 · see citing works

Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy

Petrazzuolo, A., Maiuri, M. C., Zitvogel, L., Kroemer, G., & Kepp, O. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2077898 · Cited by 36 · see citing works

Less is more: Exploring neoadjuvant immunotherapy as a de-escalation strategy in head and neck squamous cell carcinoma treatment

Cao, L., Zhong, N., Chen, Y., Li, Z., Wang, G.-R., Xiao, Y., Liu, X.-H., Jia, J., Liu, B., & Bu, L. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217095 · Cited by 36 · see citing works

Immunotherapy in Ovarian Cancer

Wang, W., Liu, J. R., & Zou, W. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.002 · Cited by 36 · see citing works

Diagnosis and treatment of epidural metastases

Yáñez, M. L., Miller, J. J., & Batchelor, T. T. (2016) · Cancer · doi:10.1002/cncr.30521 · Cited by 36 · see citing works

Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors

Ponomarenko, D. M., Клімова, І., Chapygina, Y. A., Dvornichenko, V. V., Zhukova, N. V., Орлова, Р. В., Manikhas, G. M., Zyryanov, A. V., Бурханова, Л. А., Badrtdinova, I. I., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16574 · Cited by 36 · see citing works

Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy

Castoldi, F., Vacchelli, E., Zitvogel, L., Maiuri, M. C., Pietrocola, F., & Kroemer, G. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1498285 · Cited by 33 · see citing works

Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF -mutated Urothelial Carcinoma

Rossman, P., Zabka, T. S., Ruple, A., Tuerck, D., Ramos, J. A., Liu, L., Mohallem, R., Merchant, M. A., Franco, J., Fulkerson, C. M., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0893 · Cited by 33 · see citing works

Immune-based combination therapy for esophageal cancer

Wang, H., Xu, Y., Zuo, F., Liu, J., & Yang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1020290 · Cited by 32 · see citing works

Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer

Kersh, A. E., Ng, S., Chang, Y. M., Sasaki, M., Thomas, S. N., Kissick, H. T., Lesinski, G. B., Kudchadkar, R. R., Waller, E. K., & Pollack, B. P. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1028 · Cited by 32 · see citing works

Trial watch: DNA-based vaccines for oncological indications

Pierini, S., Perales-Linares, R. F., Uribe‐Herranz, M., Pol, J. G., Zitvogel, L., Kroemer, G., Facciabene, A., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1398878 · Cited by 30 · see citing works

Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance?

Filippi, A. R., Muzio, J. D., Badellino, S., Mantovani, C., & Ricardi, U. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.53 · Cited by 29 · see citing works

Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial

Liu, Z., Wang, D., Yi, M., Yi, M., Zhang, Z., Zhong, G., Xu, L., Jiang, R., Zheng, Y., Huang, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59865-1 · Cited by 29 · see citing works

Can the co-dependence of the immune system and angiogenesis facilitate pharmacological targeting of tumours?

Mortara, L., Benest, A. V., Bates, D. O., & Noonan, D. M. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.009 · Cited by 27 · see citing works

Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future

Kasherman, L., Siu, D. H. W., Woodford, R. G., & Harris, C. A. (2022) · Cancers · doi:10.3390/cancers14061406 · Cited by 28 · see citing works

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer

Wang, W., Huang, Z., Yu, Z., Zhuang, W., Zheng, W., Cai, Z., Shi, L., Yu, X., Lou, G., Hong, W., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.572853 · Cited by 26 · see citing works

Biomimetic Active Materials Guided Immunogenic Cell Death for Enhanced Cancer Immunotherapy

Huang, G., Liu, L., Pan, H., & Cai, L. (2022) · Small Methods · doi:10.1002/smtd.202201412 · Cited by 25 · see citing works

Type of chemotherapy has substantial effects on the immune system in ovarian cancer

Vankerckhoven, A., Baert, T., Riva, M., Bruyn, C. D., Thirion, G., Vandenbrande, K., Ceusters, J., Vergote, I. B., & Coosemans, A. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101076 · Cited by 23 · see citing works

Interactions between Cisplatin and Quercetin at Physiological and Hyperthermic Conditions on Cancer Cells In Vitro and In Vivo

Oršolić, N., Odeh, D., Jembrek, M. J., Knežević, J., & Kučan, D. (2020) · Molecules · doi:10.3390/molecules25143271 · Cited by 23 · see citing works

Immunotherapy-related gastritis: Two case reports and literature review

Woodford, R. G., Briscoe, K. P., Tustin, R., & Jain, A. (2021) · Clinical Medicine Insights Oncology · doi:10.1177/11795549211028570 · Cited by 22 · see citing works

Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma

Ou, Q., Yu, Y., Li, A., Chen, J., Yu, T., Xu, X., Xie, X., Chen, Y., Lin, D., Zeng, Q., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.01.32 · Cited by 21 · see citing works

Immune profiling and immunotherapeutic targets in pancreatic cancer

Lenzo, F. L., Kato, S., Pabla, S., DePietro, P., Nesline, M., Conroy, J. M., Burgher, B., Glenn, S. T., Kuvshinoff, B. W., Kurzrock, R., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-1076 · Cited by 21 · see citing works

Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells

Otsuka, K., Mitsuhashi, A., Goto, H., Hanibuchi, M., Koyama, K., Ogawa, H., Ogino, H., Saijo, A., Kozai, H., Yoneda, H., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.05.023 · Cited by 19 · see citing works

Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review

Xu, J., Bai, Y., Li, E., Xu, N., Shi, D., & Qian, J. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2110470 · Cited by 17 · see citing works

Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients

Huber, V., Guardo, L. D., Lalli, L., Giardiello, D., Cova, A., Squarcina, P., Frati, P., Giacomo, A. M. D., Pilla, L., Tazzari, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001167 · Cited by 17 · see citing works

Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer

Yang, Z., Chen, Y., Wang, Y., Hu, M., Qian, F., Zhang, Y., Zhang, B., Zhang, W., & Han, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.807575 · Cited by 17 · see citing works

Immunotherapeutic Strategies in Non-Small-Cell Lung Cancer: The Present and the Future

Steendam, C. M. J., Dammeijer, F. F., Aerts, J. G. J. V., & Cornelissen, R. (2017) · Immunotherapy · doi:10.2217/imt-2016-0151 · Cited by 15 · see citing works

Phase I/II clinical trial of the targeted chemotherapeutic drug, folate-tubulysin, in dogs with naturally-occurring invasive urothelial carcinoma

Szigetvari, N. M., Dhawan, D., Ramos, J. A., Leamon, C. P., Klein, P. J., Ruple, A., Heng, H. G., Pugh, M. R., Rao, S. B., Vlahov, I. R., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26455 · Cited by 16 · see citing works

Can Tumor-Infiltrating Lymphocytes (TILs) Be a Predictive Factor for Lymph Nodes Status in Both Early Stage and Locally Advanced Breast Cancer?

Caziuc, A., Schlanger, D., Amarinei, G., & Dindelegan, G. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040545 · Cited by 16 · see citing works

Efficacy and Safety of HAIC-FOLFOX Plus Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-line Treatment for Unresectable Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Jiang, P., Chen, C., Tian, J., Yang, F., Jiang, Z., Hu, A., & Liu, B. (2024) · Academic Radiology · doi:10.1016/j.acra.2024.09.061 · Cited by 15 · see citing works

Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer

Massa, D., Tosi, A., Rosato, A., Guarneri, V., & Dieci, M. (2022) · Cancers · doi:10.3390/cancers14194885 · Cited by 9 · see citing works

Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory

Bloom, A. C., Bender, L. H., Tiwary, S., Pasquet, L., Clark, K. T., Jiang, T., Zheng, X., Morales‐Kastresana, A., Jones, J. C., Walters, I. B., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1625687 · Cited by 15 · see citing works

Combining Radiation Therapy With Interferons: Back to the Future

Goedegebuure, R. S. A., Vonk, C. M., Kooij, L. P., Derks, S., & Thijssen, V. L. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.02.016 · Cited by 15 · see citing works

Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders

Li, X., Liu, Y., Gui, J., Gan, L., & Xue, J. (2024) · Advanced Science · doi:10.1002/advs.202400702 · Cited by 13 · see citing works

Combined treatment of small cell lung cancer using radiotherapy and immunotherapy: Challenges and updates

Cao, Z., Deng, K., Jiang, J., Tian, K., & Wang, B. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117727 · Cited by 14 · see citing works

Conditioning neoadjuvant therapies for improved immunotherapy of cancer

Benson, Z., Manjili, S. H., Habibi, M., Guruli, G., Toor, A. A., Payne, K. K., & Manjili, M. H. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.08.007 · Cited by 14 · see citing works

Review to Understand the Crosstalk between Immunotherapy and Tumor Metabolism

Pandey, P., Khan, F., Upadhyay, T. K., & Maqsood, R. (2023) · Molecules · doi:10.3390/molecules28020862 · Cited by 13 · see citing works

Basal and Luminal Molecular Subtypes in Naturally-Occurring Canine Urothelial Carcinoma are Associated with Tumor Immune Signatures and Dog Breed

Sommer, B. C., Dhawan, D., Ruple, A., Ramos, J. A., Hahn, N. M., Utturkar, S. M., Ostrander, E. A., Parker, H. G., Fulkerson, C. M., Childress, M. O., et al. (2021) · Bladder Cancer · doi:10.3233/blc-201523 · Cited by 12 · see citing works

A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer

Miglietta, F., Ragazzi, M., Fernandes, B., Griguolo, G., Massa, D., Girardi, F., Bottosso, M., Bisagni, A., Zarrilli, G., Porra, F., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0480 · Cited by 12 · see citing works

Searching for Goldilocks: How Evolution and Ecology Can Help Uncover More Effective Patient-Specific Chemotherapies

Park, D. S., Luddy, K. A., Robertson‐Tessi, M., O’Farrelly, C., Gatenby, R. A., & Anderson, A. R. A. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3981 · Cited by 12 · see citing works

Induction treatment in patients with stage III non-small cell lung cancer

Palmero, R., Vilariño, N., Navarro-Martín, A., & Nadal, E. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-420 · Cited by 11 · see citing works

Radiotherapy and PD-L1 inhibition in metastatic NSCLC

Ruysscher, D. D. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30354-6 · Cited by 12 · see citing works

Biology and therapeutic applications of the proton-coupled folate transporter

Matherly, L. H., Schneider, M. J., Gangjee, A., & Hou, Z. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2136071 · Cited by 11 · see citing works

Role of immunotherapy in pulmonary sarcomatoid carcinoma: review of current approaches and related biomarkers

Ding, K., Peng, Z., & Xu, Y. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241249041 · Cited by 11 · see citing works

GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment

Raiter, A., Lipovettzky, J., Lubin, I., & Yerushalmi, R. (2020) · BMC Cancer · doi:10.1186/s12885-020-06835-z · Cited by 11 · see citing works

Basics of immunotherapy for epithelial ovarian cancer

Collin-Bund, V., Azaïs, H., Bibi‐Triki, S., Lecointre, L., Bétrian, S., Ángeles, M. A., Eberst, L., Faller, É., Boisramé, T., Bendifallah, S., et al. (2021) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2021.102283 · Cited by 11 · see citing works

Systems Immunology Analysis Reveals an Immunomodulatory Effect of Snail-p53 Binding on Neutrophil- and T Cell-Mediated Immunity in KRAS Mutant Non-Small Cell Lung Cancer

Hammoudeh, S. M., Venkatachalam, T., Ansari, A. W., Bendardaf, R., Hamid, Q. A., Rahmani, M., & Hamoudi, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.569671 · Cited by 10 · see citing works

Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?

Wispelaere, W. D., Annibali, D., Tuyaerts, S., Lambrechts, D., & Amant, F. C. (2021) · Cancers · doi:10.3390/cancers13092040 · Cited by 10 · see citing works

Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation

Dieci, M. V., Carbognin, L., Miglietta, F., Canino, F., Giorgi, C. A., Cumerlato, E., Amato, O., Massa, D., Griguolo, G., Genovesi, E., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02050-8 · Cited by 9 · see citing works

The Determination of Immunomodulation and Its Impact on Survival of Rectal Cancer Patients Depends on the Area Comprising a Tissue Microarray

Gruber, E. S., Oberhuber, G., Pils, D., Störk, T., Sinn, K., Gruber, S., Nica, R., Kolmer, D., Turner, S. D., Schlederer, M., et al. (2020) · Cancers · doi:10.3390/cancers12030563 · Cited by 9 · see citing works

Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood

Boustani, J., Joseph, E. L. M., Martin, E., Benhmida, S., Lecoester, B., Tochet, F., Mirjolet, C., Chevalier, C., Thibouw, D., Vulquin, N., et al. (2021) · BMC Immunology · doi:10.1186/s12865-021-00429-5 · Cited by 8 · see citing works

Modulation of Immuno-biome during Radio-sensitization of Tumors by Glycolytic Inhibitors

Gupta, S., & Dwarakanath, B. S. R. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180601101145 · Cited by 8 · see citing works

Immune Effects of Conventional Cancer Therapeutics

Demaria, S., & Galluzzi, L. (2018) · Springer Publishing Company eBooks · doi:10.1891/9781617052736.0022

Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy

Proietti, E., Moschella, F., Capone, I., & Belardelli, F. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.11.005 · Cited by 49 · see citing works

Immunomodulation by targeted anticancer agents

Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212 · see citing works

Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer

Ramakrishnan, R., & Gabrilovich, D. I. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0930-1 · Cited by 79 · see citing works

Immunological effects of conventional chemotherapy and targeted anticancer agents

Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530 · see citing works